Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSome people notice puffiness, swelling in their ankles, or a sense of bloating during the first weeks on Mounjaro — and wonder whether the medicine itself is causing water retention. The short answer: Mounjaro (tirzepatide) is not known to cause water retention directly, but several things that happen during early treatment can make fluid shifts feel noticeable. Understanding what is going on helps you tell the difference between a normal adjustment and something worth raising with a clinician. These are prescription-only medicines, and a prescriber reviews your full picture before treatment begins and at every repeat.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The first few weeks on Mounjaro often involve a significant change in how much you eat and what you eat. Tirzepatide slows gastric emptying and reduces appetite, so many people naturally cut back on carbohydrates and overall calories without consciously planning to. Carbohydrates stored in the liver and muscles as glycogen bind water — roughly three grams of water per gram of glycogen. When those stores deplete quickly, that water is released, and the body is briefly recalibrating its fluid balance. The result can feel like swelling one day and a surprisingly large drop on the scales the next.
Separately, reduced food volume can slow gut motility further, which sometimes creates a sensation of bloating or fullness that people mistake for fluid retention. The NHS tirzepatide patient information page lists nausea, constipation and indigestion among the common early side effects, all of which affect how the abdomen feels, without involving retained fluid in the medical sense.
For most people these sensations ease within two to four weeks as the body settles at the new dose. They tend to return, more mildly, after each dose increase, then settle again. Our page on Mounjaro and water covers the hydration side of this in more detail.
There is no established mechanism by which tirzepatide directly causes the kidneys to retain sodium or water in the way that, say, certain blood pressure medicines or steroids do. The GIP and GLP-1 receptors that tirzepatide activates are involved in appetite signalling, insulin secretion and gastric emptying, not in the kidney's fluid-regulation pathways in a way that would predictably cause oedema.
That said, the picture is not completely simple. People with type 2 diabetes who are on tirzepatide sometimes experience a modest early drop in blood glucose levels, and any meaningful improvement in insulin resistance can itself shift fluid slightly as the kidneys adjust. This is generally a very small, transient effect. It is worth knowing, too, that significant weight loss of any kind (through any route) can sometimes unmask mild swelling in the lower legs that was previously masked by higher body fat pressing on lymphatic vessels. This is not caused by the medicine; it is a consequence of body composition changing. You can read more about whether Mounjaro helps or hinders water retention for a closer look at this question.
If you are taking other medicines alongside Mounjaro (particularly NSAIDs, calcium channel blockers, or corticosteroids) it is worth flagging any new swelling to your prescriber, since those medicines can cause fluid retention independently.
Staying well hydrated on Mounjaro is genuinely important, and it is something people underestimate. When nausea is high, the instinct is to drink less. But lower fluid intake, combined with GI side effects like vomiting or diarrhoea (which can occur, particularly around dose increases), can push the body toward mild dehydration. Paradoxically, mild dehydration can make peripheral swelling look worse and can also impair kidney function if it becomes significant. The guidance on water intake alongside Mounjaro is practical reading for anyone in the early weeks of treatment.
There is no single target figure that applies to everyone, individual needs vary by body size, activity level and climate. Sipping water steadily through the day tends to work better than trying to drink large amounts at once, especially if nausea is present. A good practical prompt is to keep a glass of water on the kitchen worktop and take a few sips every time you pass it; it is a small habit that adds up over a day without requiring concentration.
One thing worth clarifying: concerns about tirzepatide and water infections are separate from fluid retention. If you are experiencing urinary symptoms, our page on Mounjaro and urinary tract infections addresses those specifically. If you are also curious about how tirzepatide is stored before use, our guide to frozen tirzepatide explains what you need to know about keeping it safe and effective. Separately, if you are preparing your own doses, our page on using tirzepatide with bacteriostatic water walks through the reconstitution process in detail.
Most of the fluid-related sensations people notice on Mounjaro are benign and short-lived. But there are patterns that need prompt medical attention. Swelling that is confined to one leg rather than both, swelling accompanied by redness, warmth or pain in the leg, or any swelling that comes with difficulty breathing or chest tightness should be assessed the same day, these can be signs of a deep vein thrombosis or other circulatory problem that has nothing to do with Mounjaro but needs ruling out quickly.
Similarly, facial swelling, a rash, or difficulty swallowing shortly after starting or increasing Mounjaro could indicate an allergic reaction. The MHRA's Yellow Card scheme exists so that patients and clinicians can report suspected side effects; doing so helps build the evidence base for all medicines under active monitoring. Mounjaro carries a Black Triangle (▼) status, meaning the MHRA is collecting additional post-market safety data.
If you have a question about a symptom you are experiencing, our FAQs cover common concerns, or you can get in touch with our team directly. For anyone considering starting treatment, a free consultation with our prescribers is the right first step, they assess your full health picture and will flag anything that affects suitability or monitoring needs.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.